Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies
Journal of Neurology, Neurosurgery & Psychiatry
Fecha de publicación: 10 February 2018
DOI: http://dx.doi.org/10.1136/jnnp-2017-316904
Autores: Giulia Berzero, Evgenia Karantoni, Caroline Dehais, François Ducray, Laure Thomas, Géraldine Picard, Véronique Rogemond, Gaëlle Candelier, Jean-Philippe Camdessanché, Jean-Christophe Antoine, Jérôme De Seze, Amélie Liou-Schischmanoff, Jérôme Honnorat, Jean-Yves Delattre, Dimitri Psimaras.
Background: Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer, characterised by relentless progression. The mainstay of PNS treatment is the achievement of tumour remission, while immunotherapy provides only little additional benefit. However, in historical series, immunotherapy was initiated over 6 months after neurological onset and, at that stage, neuronal loss is already extensive and irreversible.
